See more : NFI Octava S.A. (08N.WA) Income Statement Analysis – Financial Results
Complete financial analysis of electroCore, Inc. (ECOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of electroCore, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Roadrunner Transportation Systems, Inc. (RRTS) Income Statement Analysis – Financial Results
- MicroCloud Hologram Inc. (HOLO) Income Statement Analysis – Financial Results
- Flughafen Wien Aktiengesellschaft (FGWLF) Income Statement Analysis – Financial Results
- InterServ International Inc. (6169.TWO) Income Statement Analysis – Financial Results
- The AES Corporation (AESC) Income Statement Analysis – Financial Results
electroCore, Inc. (ECOR)
About electroCore, Inc.
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.03M | 8.59M | 5.45M | 3.50M | 2.39M | 992.95K | 811.46K | 254.14K |
| Cost of Revenue | 2.80M | 1.62M | 1.39M | 1.74M | 1.16M | 578.74K | 518.53K | 123.73K |
| Gross Profit | 13.23M | 6.98M | 4.07M | 1.76M | 1.23M | 414.21K | 292.93K | 130.41K |
| Gross Profit Ratio | 82.51% | 81.19% | 74.59% | 50.30% | 51.59% | 41.71% | 36.10% | 51.31% |
| Research & Development | 5.32M | 5.52M | 2.54M | 4.20M | 9.90M | 12.47M | 7.83M | 7.97M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.50M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.71M | 24.33M | 21.57M | 21.84M | 35.42M | 42.50M | 18.11M | 7.17M |
| Other Expenses | 0.00 | -6.00K | -8.30K | -17.80K | -12.00K | -344.91K | -4.89K | 7.17M |
| Operating Expenses | 32.03M | 29.85M | 24.11M | 26.04M | 45.32M | 54.97M | 25.94M | 15.14M |
| Cost & Expenses | 34.84M | 31.47M | 25.49M | 27.78M | 46.48M | 55.55M | 26.46M | 15.26M |
| Interest Income | 433.00K | 287.00K | 10.70K | 84.30K | 970.59K | 1.01M | 99.03K | 0.00 |
| Interest Expense | 0.00 | 287.00K | 0.00 | 8.34K | 0.00 | 0.00 | 7.12M | 771.25K |
| Depreciation & Amortization | 1.03M | 596.00K | 436.62K | 489.47K | 307.36K | 66.66K | 32.31K | 53.43K |
| EBITDA | -17.76M | -22.33M | -19.66M | -24.18M | -43.98M | -54.49M | -28.87M | -14.96M |
| EBITDA Ratio | -110.79% | -266.22% | -403.85% | -681.37% | -1,761.26% | -5,420.74% | -3,144.73% | -5,885.31% |
| Operating Income | -18.81M | -22.87M | -20.04M | -24.28M | -44.09M | -54.55M | -25.64M | -15.01M |
| Operating Income Ratio | -117.31% | -266.22% | -367.68% | -694.66% | -1,844.81% | -5,494.07% | -3,160.31% | -5,906.33% |
| Total Other Income/Expenses | -215.00K | 281.00K | 1.97M | -398.04K | -1.04M | -1.21M | -10.38M | -771.25K |
| Income Before Tax | -19.02M | -22.59M | -18.07M | -24.68M | -45.13M | -55.76M | -36.03M | -15.78M |
| Income Before Tax Ratio | -118.65% | -262.95% | -331.47% | -706.05% | -1,888.24% | -5,615.88% | -4,440.01% | -6,209.81% |
| Income Tax Expense | -186.00K | -431.00K | -851.20K | -1.17M | 18.00K | 2.43K | 6.88M | -44.15K |
| Net Income | -18.83M | -22.16M | -17.22M | -23.51M | -45.15M | -55.82M | -35.79M | -15.74M |
| Net Income Ratio | -117.49% | -257.94% | -315.86% | -672.55% | -1,889.00% | -5,621.66% | -4,410.88% | -6,192.44% |
| EPS | -3.42 | -4.69 | -4.36 | -9.04 | -23.05 | -28.61 | -1.36 | -1.57 |
| EPS Diluted | -3.42 | -4.69 | -4.36 | -9.04 | -23.05 | -28.61 | -1.36 | -1.57 |
| Weighted Avg Shares Out | 5.52M | 4.73M | 3.95M | 2.60M | 1.96M | 1.95M | 26.34M | 10.04M |
| Weighted Avg Shares Out (Dil) | 5.52M | 4.73M | 3.95M | 2.60M | 1.96M | 1.95M | 26.34M | 10.04M |
electroCore to Participate in the Lytham Partners Fall 2023 Virtual Investor Conference
ROCKAWAY, N.J., Oct. 05, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will be participating in the Lytham Partners Fall 2023 Investor Conference taking place virtually...
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)
Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD
electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
ROCKAWAY, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to non-invasive nerve stimulation with mobile devices.
electroCore to Participate in the LD Micro Main Event XVI Conference
ROCKAWAY, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at the LD Micro Main Event XVI Conference in Los Angeles, California...
electroCore to Present at iAccess Alpha's – Top 10 Best Ideas from the Buyside Virtual Conference
ROCKAWAY, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at iAccess Alpha's – Top 10 Best Ideas from the Buyside Virtual...
electroCore to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
ROCKAWAY, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at the H.C. Wainwright 25th Annual Global Investment Conference.
electroCore Announces Dismissal of All Litigation Related to Its 2018 Initial Public Offering
ROCKAWAY, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic and wellness company, today announced that it has been completely vindicated in the securities class actions over the company's 2018 initial public offering brought in...
electroCore, Inc. (ECOR) Q2 2023 Earnings Call Transcript
electroCore, Inc. (NASDAQ:ECOR ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Daniel Goldberger - CEO & Director Brian Posner - CFO & Corporate Secretary Conference Call Participants John Vandermosten - Zacks Swayampakula Ramakanth -...
electroCore Announces Second Quarter 2023 Financial Results
Record second quarter 2023 net sales of $3.6 million, an increase of approximately 65% over second quarter 2022 Company to host a conference call and webcast today, August 9, 2023 at 4:30 PM EDT ROCKAWAY, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- electroCore,...
electroCore to Announce Second Quarter Financial Results on Wednesday, August 9
ROCKAWAY, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the second quarter ended June 30, 2023, after the close of the market on Wednesday,...
Source: https://incomestatements.info
Category: Stock Reports